Cencora Inc.
Cencora, Inc. (COR)
Overview
Cencora, Inc. is one of the largest pharmaceutical distribution and healthcare solutions companies in the world, operating in the Healthcare sector under the Medical Distribution industry. Headquartered in Conshohocken, Pennsylvania, the company traces its roots to 1871 and took its current form in 2001 through the merger of Bergen Brunswig and AmeriSource Health Corporation, operating for over two decades as AmerisourceBergen before rebranding to Cencora in August 2023. Cencora is enormous by revenue but comparatively lean in headcount for a company its size, employing roughly 51,000 people while generating trailing-twelve-month revenue of approximately $332.8 billion (fiscal 2024 revenue was $293.96 billion, up about 12% from fiscal 2023's $262.17 billion), reflecting the thin-margin, high-volume nature of pharmaceutical wholesaling. It trades on the NYSE under ticker COR and is estimated to handle roughly one-fifth of all pharmaceuticals distributed in the United States.
What They Do & How They Make Money
Cencora does not manufacture drugs; it is the logistics and distribution backbone that sits between pharmaceutical manufacturers and the pharmacies, hospitals, physician offices, and health systems that dispense medicines to patients. The company purchases pharmaceutical products — generics, brand-name drugs, specialty and injectable medicines, over-the-counter products, vaccines, plasma and blood products, and home healthcare supplies — in bulk from manufacturers and resells and delivers them to tens of thousands of downstream customers, typically through 26 U.S. distribution centers plus additional specialty and international facilities. Because pharmaceutical distribution is a low-margin, high-turnover business, Cencora earns money primarily on volume: small percentage markups and fee-for-service arrangements with manufacturers, combined with efficient working-capital management (buying and reselling inventory quickly) and value-added services. Beyond core distribution, the company has built out higher-margin specialty services — oncology and dialysis provider support, pharmacy management, packaging and supply-chain software, data analytics for drug manufacturers, animal health distribution, and specialty logistics (including temperature-controlled and time-sensitive shipping for biologics) — that help offset the thin margins of pure distribution and account for a growing share of profitability.
Business Segments
As of its most recent annual reporting, Cencora organizes its business into two reportable segments:
- U.S. Healthcare Solutions — The core domestic pharmaceutical distribution business, delivering generic and injectable pharmaceuticals, OTC products, and home healthcare supplies to hospitals, retail and specialty pharmacies, physician practices, and long-term care facilities. This segment also houses higher-margin specialty offerings: pharmacy management and supply-chain software, packaging solutions, clinical trial support services, data analytics for pharmaceutical manufacturers, animal health (companion and production animal) distribution, and dedicated support for oncology and dialysis providers. This is by far the larger segment by revenue, given the scale of the U.S. pharmaceutical market.
- International Healthcare Solutions — Pharmaceutical wholesale distribution and commercialization support outside the U.S., serving international pharmacies, physicians, health centers, and hospitals across roughly nine Canadian distribution centers and more than 150 company-owned offices worldwide. This segment also includes World Courier, Cencora's specialty logistics arm that handles time- and temperature-sensitive transportation for biopharmaceutical products globally.
Cencora does not break out precise segment-level revenue and profit splits in its public marketing materials, but U.S. Healthcare Solutions represents the substantial majority of both revenue and operating income, consistent with the U.S. being by far the company's largest market.
Competitors
Cencora's primary competitors are the other two members of the "Big Three" U.S. pharmaceutical wholesalers, which together control the vast majority of U.S. drug distribution:
- McKesson Corporation (MCK) — the largest U.S. pharmaceutical distributor by revenue
- Cardinal Health (CAH) — the third major national full-line wholesaler
In specialty distribution, logistics, and pharmacy services, Cencora also competes with specialty distributors and pharmacy benefit/services players, and in international markets it competes with regional wholesalers such as Alliance Healthcare/Walgreens Boots Alliance-affiliated distribution networks and various country-specific pharmaceutical distributors. In its higher-margin service lines (data analytics, clinical trial logistics, packaging), it competes with specialty logistics and healthcare data firms rather than pure distributors.
Competitive Position
Cencora's moat rests on scale, entrenched relationships, and infrastructure that would be extremely costly to replicate: a nationwide network of distribution centers, decades-long contracts with manufacturers and healthcare providers, and the regulatory licensing and compliance apparatus required to legally distribute controlled substances and pharmaceuticals. The "Big Three" wholesaler structure functions as a rational oligopoly — Cencora, McKesson, and Cardinal Health collectively distribute the large majority of U.S. pharmaceuticals, and switching costs for both manufacturers and pharmacy customers are high, giving the incumbents durable, if thin-margin, volume. Cencora has also worked to diversify into higher-margin specialty pharmaceuticals (especially oncology, where injectable and complex specialty drugs carry better economics than generic distribution), consulting, and data services, which partially insulates it from generic-drug price deflation.
Key risks include the razor-thin margins inherent to distribution, which make the business highly sensitive to drug pricing trends, generic reimbursement pressure, and payer/PBM dynamics; significant legal and reputational exposure from the opioid crisis (Cencora was part of a $26 billion multi-state settlement in 2022 and separately paid $625 million in 2018 to settle federal fraud allegations related to repackaged drugs); and cybersecurity risk, underscored by a disclosed 2024 data breach exposing patient information. The company also faces customer concentration risk, since a small number of large pharmacy chains and health systems account for a substantial share of revenue, and it must continually invest in technology and specialty/biologics logistics capacity as the drug pipeline shifts toward complex, temperature-sensitive specialty and cell/gene therapies — an area where Cencora has been expanding via acquisitions such as its 2025 purchase of an 85% stake in Retina Consultants of America for $4.4 billion.